Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting.

about

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting.

Item

http://www.wikidata.org/entity/Q36208461

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Health-related quality of life ...... turalistic outpatient setting.

@ast

Health-related quality of life ...... turalistic outpatient setting.

@en

type

Item

label

Health-related quality of life ...... turalistic outpatient setting.

@ast

Health-related quality of life ...... turalistic outpatient setting.

@en

prefLabel

Health-related quality of life ...... turalistic outpatient setting.

@ast

Health-related quality of life ...... turalistic outpatient setting.

@en

P1476

Health-related quality of life ...... turalistic outpatient setting.

@en

P2093

Héctor Dueñas

http://www.w3.org/2001/XMLSchema#string

Jihyung Hong

http://www.w3.org/2001/XMLSchema#string

Maria Victoria Moneta

http://www.w3.org/2001/XMLSchema#string

William Montgomery

http://www.w3.org/2001/XMLSchema#string

Xiaomei Peng

http://www.w3.org/2001/XMLSchema#string

P2860

Duloxetine versus other anti-depressive agents for depression

Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials.

Depression and pain comorbidity: a literature review.

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.

Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.

P304

1481-1490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PPA.S89870

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Maria Haro

Diego Novick

P577

2015-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26527865

http://www.w3.org/2001/XMLSchema#string

P932

4621215

http://www.w3.org/2001/XMLSchema#string